View Rule

The direct final rule amends the Commission's regulations to add SHINE Medical Technologies, Inc.’s (SHINE) proposed accelerator-driven subcritical operating assemblies to the NRC's definition of a "utilization facility."  In 2013, SHINE submitted a two-part construction permit application for a medical radioisotope production facility that SHINE proposes to build in Janesville, Wisconsin.  The proposed accelerator-driven subcritical operating assemblies, to be housed in SHINE's irradiation facility, would be used to produce molybdenum-99 (Mo-99), a radioisotope used in medical imaging and other radioisotopes used for medical purposes.  This rule allows NRC staff to conduct an efficient and effective licensing review of the SHINE construction permit application and any subsequent operating license application.